CORDIS
EU research results

CORDIS

English EN

Beta-cell function in juvenile diabetes and obesity

Project information

Grant agreement ID: 279153

Status

Closed project

  • Start date

    1 February 2012

  • End date

    30 November 2016

Funded under:

FP7-HEALTH

  • Overall budget:

    € 7 957 282

  • EU contribution

    € 5 999 779

Coordinated by:

UPPSALA UNIVERSITET

Sweden

Objective

The number of individuals with obesity and type 2 diabetes mellitus (T2DM) is increasing. An alarming aspect is decline in age of onset of T2DM, which is coupled to rise in childhood obesity. Accentuated insulin secretion is observed early in young obese individuals. In many subjects insulin hypersecretion is evident when insulin sensitivity is essentially normal. Based on these observations we propose insulin hypersecretion as an etiological factor promoting lipid deposition, insulin resistance, cellular dysfunction and death in insulin-producing beta-cells and insulin-target brown adipocytes. Pharmacology-based treatment strategies are limited for this growing patient group and the aim of the proposal is to identify novel strategies reducing insulin hypersecretion, which has not been considered a target for intervention in young obese individuals. To address the issue, pediatric obesity clinics and academic centres with focus on beta-cell biology, brown adipocyte imaging, transcript and protein profiling, genetics, epidemiology and bioinfomatics have formed a consortium with two SMEs specialized on biomarker discovery and clinical trials and one large drug company. In the project well-characterized European patient cohorts of more than 3000 obese children will be further characterized with regard to insulin secretion and brown adipocyte mass. Currently used drugs and new principles of intervention based on novel genes, idenitifed in the project and linked with insulin hypersecretion, will be examined for effects on insulin hypersecretion in translational work including the young obese subjects and isolated human islets. Following comprehensive analysis candidate compounds/principles attenuating insulin hypersecretion will be selected, from which novel therapeutic strategies are expected to emerge. Such therapeutic strategies will be of importance for afflicted individuals and European health economy and lead to new opportunities for European industry.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

UPPSALA UNIVERSITET

Address

Von Kraemers Alle 4
751 05 Uppsala

Sweden

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 2 511 440,70

Administrative Contact

Anders Alderborn (Dr.)

Participants (11)

UNIVERSITE DU LUXEMBOURG

Luxembourg

EU Contribution

€ 380 800

PARACELSUS MEDIZINISCHE PRIVATUNIVERSITAT SALZBURG - PRIVATSTIFTUNG

Austria

EU Contribution

€ 110 400

THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE

United Kingdom

EU Contribution

€ 350 400

UNIVERSITAET LEIPZIG

Germany

EU Contribution

€ 740 600

UNIVERSITE DE GENEVE

Switzerland

EU Contribution

€ 546 266,80

PROTEOSYS AG

Germany

EU Contribution

€ 160 981,50

ASTRAZENECA UK LIMITED

United Kingdom

UPPSALA LANS LANDSTING

Sweden

EU Contribution

€ 311 799,60

SCANDINAVIAN CRO AB

Sweden

EU Contribution

€ 244 800

PIVOT BIOMEDICAL SCIENCE GMBH

Germany

EU Contribution

€ 269 690,40

GEMEINNUTZIGE SALZBURGER LANDESKLINIKEN BETRIEBSGESELLSCHAFT

Austria

EU Contribution

€ 372 600

Project information

Grant agreement ID: 279153

Status

Closed project

  • Start date

    1 February 2012

  • End date

    30 November 2016

Funded under:

FP7-HEALTH

  • Overall budget:

    € 7 957 282

  • EU contribution

    € 5 999 779

Coordinated by:

UPPSALA UNIVERSITET

Sweden